Abstract | INTRODUCTION: The B-cell receptor (BCR) is critical for the development and persistence of B-cell non-Hodgkin lymphoma (B-NHL). Protein kinase C-beta (PKC-?) has been identified as one of the key signaling hubs downstream of the BCR and constitutes a valuable target in B-NHL. As a potent PKC-? inhibitor, enzastaurin is currently being tested in Phase II/III trials. AREAS COVERED: EXPERT OPINION: While its continued clinical development is uncertain, enzastaurin should be regarded as a stepping stone for the development of future therapies; indeed, the recent research has provided valuable insight into the possible molecular mechanisms that explain its limited clinical activity especially in the treatment of DLBCL and MCL. It should be noted that there is still some interest in enzastaurin, in combination, for the treatment of WM.
|
Authors | Loic Ysebaert, Franck Morschhauser |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 20
Issue 8
Pg. 1167-74
(Aug 2011)
ISSN: 1744-7658 [Electronic] England |
PMID | 21639821
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Indoles
- Protein Kinase Inhibitors
- Protein Kinase C
- Protein Kinase C beta
- enzastaurin
|
Topics |
- Animals
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Humans
- Indoles
(pharmacology, therapeutic use)
- Lymphoma, B-Cell
(drug therapy, enzymology, metabolism)
- Protein Kinase C
(antagonists & inhibitors, metabolism)
- Protein Kinase C beta
- Protein Kinase Inhibitors
(pharmacology, therapeutic use)
|